RadioMedix   Report issue

For profit Phase 2 Phase 3
Founded: Houston TX United States (2006)

Organization Overview

First Clinical Trial
2006
NCT00442533
First Marketed Drug
2020
cu-64 dotatate
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

RADIOMEDIX | Radiomedix, Inc.